Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents

• Published in: Journal of the American College of Cardiology Vol. 50; no. 14; pp. 1299 - 1304
• Main Authors: Morice, Marie-Claude, MD, FACC, FESC, Serruys, Patrick W., MD, PhD, FACC, Barragan, Paul, MD, Bode, Christoph, MD, Van Es, Gerrit-Anne, PhD, Stoll, Hans-Peter, MD, Snead, David, PhD, Mauri, Laura, MD, MSc, FACC, Cutlip, Donald E., MD, FACC, Sousa, Eduardo, MD, PhD, FACC
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.10.2007
• Subjects: Cardiovascular; Internal Medicine; major adverse cardiac events; SES; bare-metal stent(s); target lesion revascularization; myocardial infarction; sirolimus-eluting stent(s); Academic Research Consortium; BMS; QCA; TVR; ARC; quantitative coronary angiography; MACE; target vessel revascularization; TLR; MI
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2007.06.029

Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents: Five-Year Results of the RAVEL Trial Marie-Claude Morice, Patrick W. Serruys, Paul Barragan, Christoph Bode, Gerrit-Anne Van Es, Hans-Peter Stoll, David Snead, Laura Mauri, Donald E. Cutlip, Eduardo Sousa This study examined 5-year clinical outcomes in RAVEL (A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of a coronary drug-eluting stent. The 1-, 3-, and 5-year rates of survival free from target lesion revascularization (TLR) were 99.2%, 93.8%, and 89.7%, respectively, in 120 patients randomly assigned to treatment with sirolimus-eluting stents (SES) versus 75.9%, 75.0%, and 74.0% in 118 patients assigned to bare-metal stents (BMS) (p < 0.001). Rates of all major adverse cardiac events, including all deaths, myocardial infarction, and TLR, were 25.8% in patients treated with SES versus 35.2% in patients assigned to BMS (p = 0.03). Rates of stent thrombosis were similar in both groups.